Non-treatment-related chronic myeloid leukemia as a second malignancy

“…Theauthorssuggestedthatthetimeintervalforexpansion of the malignant clone was at least 16 months [14]. Our patient developed CML relatively shortly after treatment of DLBCLwithlatencytimeofonly9monthsbetweenthe2dis-eases, suggesting the hypothesis of non-treatment related CML (nTr-CML) occurring as well as a primary de novo disorder.Indeed,nTr-CMLasasecondmalignancyisarare entity [15,16]. 9 case reports of nTr-CML occurring in patients with previous neoplasms, who had not been treated with chemotherapy, are summarized in table 2.…”

Section: Discussionmentioning

confidence: 99%

“…9 case reports of nTr-CML occurring in patients with previous neoplasms, who had not been treated with chemotherapy, are summarized in table 2. The latency periodwascalculatedasthemonthsbetweentheinitialdiagnosisofthefirstmalignancyandtheappearanceofCML.All patientswereolderthan50years [5,[16][17][18][19].Thus,thisentity was not previously described in the younger population. To our knowledge, this is the first report of a child who developedCMLasasecondmalignancyafterDLBCL.…”

Section: Discussionmentioning

confidence: 99%

Chronic Myeloid Leukemia as a Secondary Malignancy after Lymphoma in a Child. A Case Report and Review of the Literature

Zahra

Fredj²,

Youssef³

et al. 2012

Onkologie

View full text Add to dashboard Cite

Background: Philadelphia chromosome-positive chronic myeloid leukemia (CML) in children is very rare. CML occurring as a secondary malignancy in individuals treated for diffuse large B-cell lymphoma (DLBCL) is also rare. Case Report: We present the case of a 5-year-old female patient who developed a right orbital mass that was diagnosed as DLBCL. 9 months after receiving treatment for DLBCL, she presented with a white cell count of 250,000/mm³. Peripheral blood and bone marrow (BM) evaluation revealed a myeloproliferative disorder. Cytogenetic and molecular studies demonstrated the presence of t(9;22). CML following DLBCL has not been previously described in the younger population. To our knowledge, this is the first report of a child who developed a CML as a second malignancy after DLBCL. Therapy-related CML and non-therapy-related secondary CML are discussed as potential explanations of this highly unusual clinical presentation. Conclusion: Hematological disorders such as CML may occur after lymphomas. With the increased use of BM cytogenetic studies during staging for lymphoid malignancies, future studies may be able to clarify the question of whether the CML clone in some of these patients existed before treatment for lymphoma.

show abstract

“…Philadelphia (Ph) chromosome (t(9; 22)(q34; q11))-positive chronic myeloid leukemia (CML) occurring as a secondary malignancy in patients who were treated for non-Hodgkin lymphoma (NHL) is very rare [1,2]. The association between B-cell–derived lymphoid neoplasias and myeloproliferative disorders is not clear [1].…”

Section: To the Editormentioning

confidence: 99%

Chronic Myeloid Leukemia as a Secondary Malignancy Following Treatment of Diffuse Large B-Cell Lymphoma

Demiriz¹,

Tekgündüz²,

Bozdağ³

et al. 2014

Tjh

View full text Add to dashboard Cite

Non-treatment-related chronic myeloid leukemia as a second malignancy

Cited by 7 publications

References 65 publications

Chronic myeloid leukemia as a secondary malignancy after ALK-positive anaplastic large cell lymphoma

Chronic myeloid leukemia as a secondary malignancy after ALK-positive anaplastic large cell lymphoma

Chronic Myeloid Leukemia as a Secondary Malignancy after Lymphoma in a Child. A Case Report and Review of the Literature

Chronic Myeloid Leukemia as a Secondary Malignancy Following Treatment of Diffuse Large B-Cell Lymphoma

Contact Info

Product

Resources

About